All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 4, 2023
Breaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeksBreaking News: Try BioWorld for free for two weeks
  • Bone marrow illustration with doctor background

    Cancer progression pathway and possible therapy for Fanconi anemia identified

    Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
  • IL-2RG blockade as a therapeutic strategy for prevention and treatment of T-cell-mediated disease

    The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.
  • Cancer progression pathway and possible therapy for Fanconi anemia identified

    Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
  • IL-2RG blockade as a therapeutic strategy for prevention and treatment of T-cell-mediated disease

    The interleukin-2 receptor subunit γ (IL-2RG), also known as γc cytokine receptor or CD132, family of cytokines includes interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15 and IL-21. These γc cytokines exert broad pleiotropic effects on the innate and adaptive immune system, and they all share the IL-2RG chain as part of its signaling receptor complex. Researchers from Regeneron Pharmaceuticals Inc. aimed to assess whether targeting γc cytokines may serve as a strategy for the prevention and treatment of T-cell-mediated disease.
  • Other news to note for Feb. 3, 2023

    Additional early-stage research and drug discovery news in brief.
  • Discovery of new antileishmanial agents

    Researchers from Central Drug Research Institute (CDRI) and the Academy of Scientific & Innovative Research (AcSIR) have synthesized and evaluated a series of novel antileishmanial agents. Synthesis and optimization of a series of halogen-rich salicylanilides led to the discovery of compounds [I] and [II], which demonstrated the best antileishmanial activity, with IC50 values of 2.89 μM and 2.09 μM, respectively against Leishmania donovani amastigote.
  • Tonix Pharmaceuticals to develop TNX-3900 series of oral antivirals

    Tonix Pharmaceuticals Holding Corp. has announced it plans to develop the TNX-3900 series of oral antivirals as monotherapy or in combination with other antivirals, following an agreement whereby it has acquired all of the assets of Healion Bio Inc., including its entire portfolio of next-generation antiviral technology assets.
  • Xinthera patents new MAPKAPK2 inhibitors

    Xinthera Inc. has divulged pyridinones acting as MAP kinase-activated protein kinase 2 (MAPKAPK2) inhibitors reported to be useful for the treatment of autoimmune disease, cancer, fibrosis, metabolic diseases, inflammation and cardiovascular and cerebrovascular disorders.
  • A 13-protein marker panel may predict osteoarthritis progression

    Joint pain illustration
  • Incyte divulges GTPase KRAS mutant inhibitors

  • Philadelphia University describes new COX-2 inhibitors

  • TRF2 prevents telomere shortening and prolongs cardiomyocyte survival in DMD

    Chromosome with shortened telomeres
  • Newave Pharmaceutical and Guangzhou Lupeng Pharmaceutical present EGFR mutant inhibitors

  • Kanaph Therapeutics and Yungjin Pharmaceutical identify new PTPN11 inhibitors

  • Pliant's integrin inhibitor PLN-101095 cleared to enter clinic for solid tumors

    Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Listen to BioWorld Science

BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness which in many ways goes against the mainstream health care state of mind about obesity.
Listen now

Conferences

  • Low CHEK2, ATM and PALB2 expression correlates with better overall survival in CRC

    Biomarkers
    Outcomes after therapy with DNA-damaging agents such as irinotecan or oxaliplatin have been seen to improve in patients with homologous recombination-deficient colorectal cancer (HRD CRC) compared to those who have HR proficient CRC (HRP CRC).
  • CF33-hNIS-antiPDL1 shows efficacy in models of gastric cancer peritoneal carcinomatosis

    Cancer
    Genetically modified derivatives of the chimeric oncolytic virus (OV) CF33 have previously shown cancer selectivity and oncolytic potency against various solid tumors.
  • Illustration of DNA, digestive system

    CXCL1 promotes colon cancer progression through NF-κB/P300 activation

    Cancer
    Upregulation of C-X-C motif chemokine ligand 1 (CXCL1) has been validated in patients with colorectal cancer (CRC), but the mechanism behind CXCL1 affecting CRC tumor cell progression is not clear. Gene-editing techniques were used to investigate the impact of CXCL1 knockout and overexpression in...
  • Illustration of the liver, gallbladder, stomach, and pancreas

    GM-CSFR signaling in cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Biomarkers
    Previous studies have demonstrated that increased expression of the granulocyte-macrophage colony-stimulating factor (GM-CSF) correlated with poor prognosis in patients with cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC). In the current study, a research team at the University...
More in Conferences

Today's news in brief

  • Other news to note for Feb. 3, 2023

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • State University of New Jersey and Tufts University synthesize new antibacterial compounds

  • Dice Alpha patents new IL-17A production inhibitors

  • Chan Zuckerberg Biohub and Stanford University present new CDK19 inhibitors

  • Lung Therapeutics discloses new ENaC blockers

  • Biogen and C4 Therapeutics divulge new IRAK-4-targeting PROTACs

  • Medshine Discovery describes new GTPase KRAS mutant inhibitors

  • Northwest Agriculture & Forestry University patents new TRPC6 antagonists

  • Prazer Therapeutics presents new MAPK14 inhibitors

  • Glenmark Pharmaceuticals discloses new MAP4K1 inhibitors

  • Roche patents new antibacterial compounds

Cancer

  • Dividing breast cancer cell.

    NRG1 and hyperglycemia tied to breast cancer progression

    Several studies on the effect of hyperglycemia on malignant tumor progression have been performed; hyperglycemia is known to be a risk factor for breast cancer-related mortality, since it causes aberrant gene expression by altering the epigenome (hyperglycemic memory).
  • Combined targeting of mevalonate pathway/PRC2 shows anticancer effect in BAP1-mutated mesothelioma

  • IND-enabling toxicology studies of Sonnet's SON-1210 in NHPs support progression to clinic

    Immuno-oncology
  • Novel organo-arsenic compound suppresses osteosarcoma growth by inhibiting PDK-1

    Targeted therapy
  • TVM Capital invests in Recurv Pharma to advance novel taxane RP-001

    Financings
More in Cancer
black cortellis ad

Infection

  • Coronavirus, mRNA and syringe

    Greenlight cleared to begin first-in-human study of mRNA COVID-19 vaccine candidate GLB-COV2-043

    Immune
    Greenlight Biosciences Holdings PBC has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a first-in-human phase I/II trial of its mRNA vaccine candidate against COVID-19, GLB-COV2-043, as a booster for previously vaccinated individuals.
  • Tecnimede-Sociedade Tecnico-Medicinal discovers new compounds for tuberculosis

    Patents
    Tecnimede-Sociedade Tecnico-Medicinal SA has described heterocyclic compounds reported to be useful for the treatment of tuberculosis.
  • University of Manchester patents new antimicrobials for fungal and bacterial infections

    Patents
    University of Manchester researchers have...
  • Chinese Academy of Sciences institutes divulge new compounds for infection and inflammatory disorders

    Coronavirus
  • Cas12a2 elicits abortive infection and can be repurposed as an RNA-guided RNA-targeting tool

    Drug design, drug delivery and technologies
  • What stops a bad guy in the lung? A good guy in the lung, of course

    Cancer
  • Taxis Pharmaceuticals patents new antibacterial compounds

    Patents
More in Infection

Neurology/Psychiatric

  • Brain and DNA

    Herophilus conducts in vivo studies of HRP-12975 for Rett syndrome

    Genetic/Congenital
    Herophilus Inc. is conducting in vivo studies of lead candidate HRP-12975, a small-molecule therapy for Rett syndrome, with funding from the Rett Syndrome Research Trust. The company is generating efficacy and safety data with HRP-12975 using genetic mouse models of Rett syndrome.
  • Illustration of antibodies attacking nerve cells

    Lapix receives support from FDA for IND-enabling plan for LPX-TI641

    Immune
    Lapix Therapeutics Inc. has announced the successful outcome of its pre-IND meeting request with the FDA to achieve alignment on the company's IND-enabling plan for LPX-TI641, being developed for neuro-autoimmune indications such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders...
  • Toray Industries presents κ-opioid receptor agonists for pain

    Patents
    Toray Industries Inc. has divulged aminocyclohexane derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of pain.
  • Light micrograph of skeletal muscle.

    Inmune Bio uses DN-TNF biologic to target soluble TNF to increase muscle regeneration in DMD model

    Inmune Bio Inc., together with a collaborator at University of California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a dominant-negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Duchenne muscular dystrophy (DMD) and showed a...
  • Brain and DNA

    NUP50 gene variation tied to ALS risk, researchers find

    Biomarkers
    Amyotrophic lateral sclerosis (ALS) is the most frequent adult-onset motor neuron disease, and it is pathologically related with frontotemporal dementia (FTD). Genetic studies have identified C9ORF72 as a major genetic cause of ALS/FTD. Further genetic analyses and validation studies have...
More in Neurology/Psychiatric

Immune

  • T-cell study reveals autoimmune component of atherosclerosis

  • Zedira presents new TGM2 inhibitors

  • Escient gains IND clearance for first-in-human study of MRGPRX2 antagonist EP-262

  • Redeeming neutrophils could be anticancer approach

  • CD64 overexpression can protect cell therapeutics from antibody-mediated killing

  • Poolbeg to study use of POLB-001 to dampen CRS in patients receiving CAR T-cell therapy

  • Intranasally administered gonococcal OMVs plus microsphere-encapsulated IL-12 show efficacy in vivo

  • Trex Bio and Lilly enter collaboration and license agreement for therapies for immune-mediated diseases

  • NEO-TRA1, a novel non-α agonist of the IL-2 receptor that selectively expands Treg populations

  • Analyzing TB T-cell response gives clues to vaccines, and TB itself

Endocrine/Metabolic

  • Illustration of diabetic foot ulcer, cross section of wound

    Reactivation of fetal protein can lead to improved diabetic wound healing

    Diabetes
    Researchers at Indiana University School of Medicine are exploring avenues to heal wounds by identifying proteins that are active in fetuses, but largely inactive in adults and absent in diabetic adults. They have identified a protein called nonselenocysteine-containing phospholipid hydroperoxide...
  • Discovery of novel α-glucosidase inhibitors’ hypoglycemic activity

  • Fusion protein has metabolic benefits in mice, macaques

    Drug design, drug delivery and technologies
  • HBM Alpha completes seed financing to advance programs for congenital adrenal hyperplasia and PCOS

    Financings
  • Medi & Gene describes new peptides for diabetes

    Patents
More in Endocrine/Metabolic
cortellis ad

Biomarkers

  • Tracking metastases by gene expression unveils four subtypes of cancer

    Genomics
    Cells that break away from a tumor and colonize other regions of the body express genes that are different from those of the cancer from which they originate. Now, a Baylor College of Medicine study has found that metastases can be classified into four cancer subtypes regardless of the primary...
  • Altered plasma proteins tied to progression in castration-resistant prostate cancer

    Cancer
    Androgen deprivation therapy (ADT) is still the main treatment option for locally advanced and metastatic prostate cancer (PCa); however, most patients receiving ADT develop resistance to treatment and relapse, with a more aggressive form of cancer, castration-resistant prostate cancer (CRPC).
  • Plasmatic GAS6 levels predict acute heart failure mortality risk

    Cardiovascular
    Heart failure still remains a leading cause of death worldwide. Improving risk stratification and prognostic analysis tools is required to aid in the management of the disease.
  • Study reveals new risk loci for otosclerosis

    Ear, Nose and Throat
  • Hepsin, IL-8 and OPG as novel blood-based biomarkers in CRC

    Conferences
  • Low AXL expression correlates with better survival in cholangiocarcinoma

    Conferences
  • HLA genes tied to improved survival of CRC patients on ICI therapy

    Conferences
More in Biomarkers

Gastrointestinal

  • Rise Therapeutics to advance R-3750 immunotherapy for ulcerative colitis

    Immunotherapy
    Rise Therapeutics LLC has received FDA clearance for its IND application to proceed with a phase I trial of R-3750, a synthetic biology-based cellular immunotherapy being developed for the treatment of inflammatory bowel disease. The phase I trial...
  • ATF3 modulation found as an approach to treat hepatic steatosis

    Hepatocellular death is an important process for liver homoeostasis by elimination and replacement of impaired hepatocytes. Hepatocellular death occurs little under normal conditions in the healthy liver, and it plays a key role as a trigger of...
  • Researchers present new NLRP3 inflammasome inhibitors

    Patents
    Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.
  • Exegi Pharma cleared to study EXE-346 for management of IPAA patients

    FDA
    Exegi Pharma LLC has received FDA clearance of its IND application for EXE-346, allowing the company to initiate a clinical trial to evaluate EXE-346 in the management of excessive stool frequency in patients with an ileal pouch-anal anastomosis...
  • Researchers identify new bacterial species in inflammatory bowel disease

    Researchers from University Medical Center Utrecht and Yale University School of Medicine have recently described two novel, strictly anaerobic Allobaculum strains, 128T and 539T, isolated from the feces of humans with inflammatory bowel disease...
  • Shanghai Leadopharma Technology discloses new TRPA1 antagonists

    Patents
    Shanghai Leadopharma Technology Co. Ltd. has presented transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists reported to be useful for the treatment of irritable bowel syndrome, Crohn's disease, ulcerative colitis,...
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • Rethinking obesity: Fitness may be more directly linked to health than weight
  • Looking ahead to 2023: CEOs contemplate the new normal
  • Psychedelic evolution: Mindset Pharma looks to change mental health treatment
  • $1B+ biopharma deals keep values afloat, even amid muted volume
  • Extending the human lifespan
  • New therapies vie to change fatal course of amyotrophic lateral sclerosis
  • Biopharma’s correction? 2022 1Q investments are both up and down
  • Who advises the CDC on big COVID decisions and how’s that working out?
  • Long COVID: Potentially the next public health crisis
  • What happens when your inventor is an artificial intelligence?

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing